Analysis of everolimus starting dose as prognostic marker in HR+ mBC patients treated with everolimus (EVE) + exemestane (EXE): Results of the 3rd interim analysis of the non-interventional trial BRAWO.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Peter A. Fasching, Eva-Maria Grischke, Florian Schuetz, Thomas Decker, Christoph Uleer, Christoph Salat, Frank Foerster, Marcus Schmidt, Christoph Mundhenke, Hans Tesch, Christian Jackisch, Pauline Wimberger, Bahriye Aktas, Mark-Oliver Zahn, Oliver Tome, Wilhelm Bloch, Sven Hanson, Thomas Fischer, Joerg Schubert, Diana Lueftner
Institutions: Universitätsklinikum Erlangen, Universitäts Frauenklinik, University of Tübingen, University Hospital Heidelberg, Klinikum Chemnitz, Johannes Gutenberg University Mainz, Christian-Albrechts-Universität zu Kiel, Sana Klinikum Offenbach, University Hospital Carl Gustav Carus, Technische Universität Dresden, Essen University Hospital, German Sport University Cologne, Novartis (Germany), Winicker Norimed GmbH (Germany), Stiftung Charité, Charité – Universitätsmedizin Berlin
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2621490532